Physician

Ahmed M Abdel-Megid, M.D.

According to 2025 Medicare claims, Ahmed Abdel-Megid, M.D. (NPI: 1134313745) practices rheumatology in the Lakewood-New Brunswick, NJ market, with the plurality of this provider's patient population coming from Somerset, NJ. This provider's primary affiliated billing organization is RHEUMATOLOGY CENTER OF NEW JERSEY INC. (NPI: 1669796272; TIN: 27-2185943) and primary practice location at 08876-2000.

Abdel-Megid's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,052 traditional Medicare patients, billed 321,012 HCPCS/CPT codes, and received $3,237,004 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 4,012 prescription claims across 873 beneficiaries totaling $5,564,738 in drug costs, led by Enbrel Sureclick (Etanercept). Open Payments data shows 143 records totaling $3,406. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $428,638 to $3,237,004. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,588,675 to $5,564,738. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	665	25,883	$428,638
2016	682	83,789	$1,014,195
2017	742	101,096	$1,355,941
2018	853	131,699	$2,089,860
2019	741	136,723	$2,197,500
2020	750	177,193	$2,742,772
2021	938	233,497	$3,222,533
2022	871	239,875	$2,751,109
2023	965	264,897	$2,772,410
2024	1,052	321,012	$3,237,004

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	578	3,687	$1,588,675
2016	615	3,884	$1,935,070
2017	670	4,034	$1,949,362
2018	724	4,318	$1,703,221
2019	675	3,411	$1,465,527
2020	696	3,470	$1,570,399
2021	712	3,594	$2,091,667
2022	838	4,377	$3,682,940
2023	996	5,348	$4,857,710
2024	873	4,012	$5,564,738

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	213	213	$195
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	890	2,172	$109
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	288	403	$77
96401	Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle	272	1,429	$65
J0897	Injection, denosumab, 1 mg	188	17,820	$20

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Enbrel Sureclick	Etanercept	154	5,376	$1,404,166
Stelara	Ustekinumab	32	2,352	$655,123
Humira(Cf) Pen	Adalimumab	77	2,520	$631,807
Cosentyx Sensoready Pen	Secukinumab	34	1,120	$289,152
Taltz Autoinjector	Ixekizumab	39	1,092	$258,782

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	143	$3,406	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ahmed M. Abdel-Megid, M.D.?

Tedicare shows public-source Medicare data for Ahmed M. Abdel-Megid, M.D. (NPI 1134313745), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ahmed M. Abdel-Megid, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Ahmed M. Abdel-Megid, M.D.?

Ahmed M. Abdel-Megid, M.D. is linked to RHEUMATOLOGY CENTER OF NEW JERSEY INC. (billing NPI 1669796272) in the available physician profile data.

Does Ahmed M. Abdel-Megid, M.D. have Open Payments data?

Ahmed M. Abdel-Megid, M.D. has 143 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.